论文部分内容阅读
世界经济的全球化和市场竞争日趋激烈。这个趋势引发全球超大规模的跨国制药公司购并活动高潮迭起,并进一步推动医药高新技术领域的竞争。改革开放以来,我国的制药产业取得了长足的进步。但和发达国家制药公司相比,我国制药业仍处于资源分散、研究和开发薄弱、竞争力低下的状况,发展面临严峻的挑战。制药业在全球市场资本中地位显赫据金融时报报道,对世界500强企业按市场资本总额分析的结果表明,制药业2000年排名第四,位于 IT 硬件、银行、电信之后,2001年跃居第二位,仅在银行之后,超过电信和 IT 硬件业。可见制药业在全球市场资本中占有重要地位。医药企业进入全球市场资本500强共有29家。全球市场资本实力最雄厚的25家
The globalization of the world economy and market competition have become increasingly fierce. This trend has triggered the upsurge of mergers and acquisitions by the world’s largest multinational pharmaceutical companies and further promoted the competition in hi-tech fields of medicine. Since the reform and opening up, China’s pharmaceutical industry has made great strides. However, compared with pharmaceutical companies in developed countries, China’s pharmaceutical industry is still in a situation of resource fragmentation, weak research and development, and low competitiveness. Its development faces severe challenges. According to the Financial Times, according to the analysis of the world’s top 500 enterprises in terms of market capitalization, the pharmaceutical industry ranked fourth in 2000 after IT hardware, banking and telecom, ranking first in 2001 Second, beyond the bank, more than telecommunications and IT hardware. Visible pharmaceutical industry in the global market capital occupies an important position. Pharmaceutical companies to enter the global market a total of 29 Fortune 500. 25 most powerful global capital markets